Is Crop Life Scienc overvalued or undervalued?

As of 4 September 2025, Crop Life Science has moved from a fair to an attractive valuation grade, indicating a positive shift in its market perception. The company is currently considered undervalued, with a PE ratio of 14.58, an EV to EBITDA of 8.41, and a PEG ratio of 1.52. These figures suggest that the company is trading at a reasonable valuation compared to its earnings growth potential.
In comparison to its peers, Crop Life Science's valuation metrics are significantly more favorable. For instance, P I Industries is deemed very expensive with a PE ratio of 35.21, while Bayer CropScience also shows high valuation at a PE of 38.78. In contrast, Crop Life Science's EV to Sales ratio of 0.67 further underscores its attractive valuation relative to the industry. Notably, the company has outperformed the Sensex year-to-date, with a return of 11.67% compared to the Sensex's 4.61%, reinforcing its potential as a worthwhile investment.